PharmaResearch Co Ltd
KOSDAQ:214450
PharmaResearch Co Ltd
Total Assets
PharmaResearch Co Ltd
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Assets
₩855.7B
|
CAGR 3-Years
26%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Assets
₩21.1T
|
CAGR 3-Years
55%
|
CAGR 5-Years
40%
|
CAGR 10-Years
25%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Assets
₩2.8T
|
CAGR 3-Years
10%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Total Assets
₩939.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
N
|
NatureCell Co Ltd
KOSDAQ:007390
|
Total Assets
₩72B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
11%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Assets
₩409B
|
CAGR 3-Years
16%
|
CAGR 5-Years
37%
|
CAGR 10-Years
27%
|
|
PharmaResearch Co Ltd
Glance View
In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.
See Also
What is PharmaResearch Co Ltd's Total Assets?
Total Assets
855.7B
KRW
Based on the financial report for Dec 31, 2024, PharmaResearch Co Ltd's Total Assets amounts to 855.7B KRW.
What is PharmaResearch Co Ltd's Total Assets growth rate?
Total Assets CAGR 5Y
26%
Over the last year, the Total Assets growth was 60%. The average annual Total Assets growth rates for PharmaResearch Co Ltd have been 26% over the past three years , 26% over the past five years .
You don't have any saved screeners yet